^
Association details:
| Biomarker: | EML4-ALK fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EP14.01-001 SCLC Transformation from ALK-rearranged Lung Adenocarcinoma after Alectinib Resistance and Response to Atezolizumab: Case Report
Published date:
07/12/2022
Excerpt:
A 77-year-old man... was diagnosed with ALK-positive stage IVB NSCLC...The biopsy was subjected to NGS analysis, and EML4-ALK was identified….Based on these findings, the patient was administered with atezolizumab (1200mg d1) in combination with etoposide (0.13g d1-d3) and carboplatin (350mg d1). After treatment, CT scan showed the left neck mass was significantly reduced with a partial response until in December, 2020.
Secondary therapy:
carboplatin + etoposide oral
